Pravastatin detailed information

Pravastatin detailed information

Clinical data
ATC code	C10AA03 (WHO)
Pharmacokinetic data
Protein binding	50%
Elimination half-life	77 hours
Identifiers
IUPAC name 3,5-dihydroxy-7- [6-hydroxy-2-methyl-8- (2-methylbutanoyloxy)- 1,2,6,7,8,8a- hexahydronaphthalen-1-yl]- heptanoic acid
CAS Number	81093-37-0
PubChem CID	54687
DrugBank	APRD00328
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H36O7
Molar mass	424.528 g/mol

WikiDoc Resources for Pravastatin detailed information
Articles
Most recent articles on Pravastatin detailed information Most cited articles on Pravastatin detailed information Review articles on Pravastatin detailed information Articles on Pravastatin detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Pravastatin detailed information Images of Pravastatin detailed information Photos of Pravastatin detailed information Podcasts & MP3s on Pravastatin detailed information Videos on Pravastatin detailed information
Evidence Based Medicine
Cochrane Collaboration on Pravastatin detailed information Bandolier on Pravastatin detailed information TRIP on Pravastatin detailed information
Clinical Trials
Ongoing Trials on Pravastatin detailed information at Clinical Trials.gov Trial results on Pravastatin detailed information Clinical Trials on Pravastatin detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Pravastatin detailed information NICE Guidance on Pravastatin detailed information NHS PRODIGY Guidance FDA on Pravastatin detailed information CDC on Pravastatin detailed information
Books
Books on Pravastatin detailed information
News
Pravastatin detailed information in the news Be alerted to news on Pravastatin detailed information News trends on Pravastatin detailed information
Commentary
Blogs on Pravastatin detailed information
Definitions
Definitions of Pravastatin detailed information
Patient Resources / Community
Patient resources on Pravastatin detailed information Discussion groups on Pravastatin detailed information Patient Handouts on Pravastatin detailed information Directions to Hospitals Treating Pravastatin detailed information Risk calculators and risk factors for Pravastatin detailed information
Healthcare Provider Resources
Symptoms of Pravastatin detailed information Causes & Risk Factors for Pravastatin detailed information Diagnostic studies for Pravastatin detailed information Treatment of Pravastatin detailed information
Continuing Medical Education (CME)
CME Programs on Pravastatin detailed information
International
Pravastatin detailed information en Espanol Pravastatin detailed information en Francais
Business
Pravastatin detailed information in the Marketplace Patents on Pravastatin detailed information
Experimental / Informatics
List of terms related to Pravastatin detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

In medicine and pharmacology, pravastatin (Pravachol® or Selektine®) is a member of the drug class of statins, used for lowering cholesterol and preventing cardiovascular disease.

Pravastatin was identified originally in a bacterium called Nocardia autotrophica by researchers of the Sankyo Pharma Inc. It is presently being marketed outside Japan by the pharmaceutical company Bristol-Myers Squibb.

In 2003, Bristol-Myers Squibb announced in a magazine advertisement that pravastatin is no longer the only statin approved by the FDA proven to reduce the risk of cardiovascular disease, and that rosuvastatin, another statin, is approved to reduce this risk.

The U.S. Food and Drug Administration approved a generic version of Pravastatin for sale in the United States for the first time on April 24, 2006. Generic Pravastatin Sodium Tablets (10mg, 20mg and 40mg) are manufactured by TEVA Pharmaceuticals in Kfar Sava, Israel. FDA Press Release

In 2005, Pravachol was the 22nd highest-selling brand-name drug in the United States. FDA Press Release

External links

• Pravachol information from the National Institute of Health
• Package insert for Pravachol

Template:WikiDoc Sources